Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment

Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment

PurposeHigh tumor burden has emerged as a negative predictor of efficacy in chimeric antigen receptor T-cell therapy (CART) in patients with refractory or relapsed large B-cell lymphoma. This study analyzed the deviation among imaging-based tumor burden (TB) metrics and their association with progre...

Full description

Bibliographic Details
Main Authors: Michael Winkelmann, Veit L. Bücklein, Viktoria Blumenberg, Kai Rejeski, Michael Ruzicka, Marcus Unterrainer, Christian Schmidt, Franziska J. Dekorsy, Peter Bartenstein, Jens Ricke, Michael von Bergwelt-Baildon, Marion Subklewe, Wolfgang G. Kunz
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
CAR T-cell therapy
Lugano criteria
RECIL
MTV
tumor burden assessment
PET/CT (18)F-FDG
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.974029/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.974029/full

Similar Items